Herpes Zoster
Conditions
Interventions
brivudine tablets treatment group:NA
Sponsors
The Second Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Clear clinical diagnosis: Meets the diagnostic criteria for acute herpes zoster (rash = 4. 3. Age range: Age >= 18 years and <= 85 years. 4. Informed consent: Participants must fully understand the purpose, methods, potential risks and benefits of the study, and sign a written informed consent form voluntarily.
Exclusion criteria
Exclusion criteria: 1. Drug contraindications: Allergy to brivudine or its main components. 2. Severe immune deficiency or suppression, such as patients with severe congenital immune deficiency, patients with severe rheumatic immune diseases undergoing hormone shock therapy, and patients in the perioperative period after stem cell transplantation. 3. During the screening period, clinical laboratory tests show platelet count (PLT) 5×ULN, albumin 2.5×ULN), or severe kidney function impairment (such as eGFR = 3×ULN). Excluded from the exclusion criteria are patients with well-controlled tumors, patients with stable vital signs after surgery, patients with mild to moderate chronic liver function impairment (ALT or AST = 30 ml/min/1.73m², serum creatinine < 3×ULN), and patients with a history of organ transplantation but stable function. 5. Patients who have recently used or are currently using or plan to receive (within 4 weeks) drugs containing fluorouracil groups (5-fluorouracil or other drugs), including their topical formulations, prodrugs (such as capecitabine, tegafur, floxuridine, flucytosine), and compound preparations or other fluorouracil drugs containing these active ingredients. 6. Pregnant or lactating patients. 7. Patients who have participated in other drug clinical trials within the past 3 months. 8. Patients with a recent history of alcohol abuse or drug abuse. Alcohol abuse is defined as consuming more than 14 units of alcohol per week, where 1 unit is approximately 360ml of beer with 5% alcohol content, 45ml of spirits with 40% alcohol content, or 150ml of wine with 12% alcohol content. 9. Severe mental and psychological disorders, such as depression, bipolar disorder, and other conditions where the investigator deems the patient unable to follow the trial protocol. 10. Patients with concurrent chronic pain disorders (such as peripheral neuropathy, chronic neuralgia, chronic low back pain, arthritic pain, cancer pain, etc.) or long-term use of analgesic drugs (such as opioids, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute phase VAS score at the end of treatment;Pain relief time;Blister cessation time;Crust formation time Sleep quality;Crust formation time Sleep quality;Clinical cure rate at the end of treatment;Occurrence of adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS score 30 days after treatment;Skin quality of life score 30 days after treatment;VAS score 90 days after treatment;Skin quality of life score 90 days after treatment;Incidence of postherpetic neuralgia 90 days after treatment;Changes in liver and kidney function and hematological related indicators before and after treatment;Occurrence of adverse reactions of bromovinyl in different populations and different parts of herpes zoster patients; | — |
Countries
China
Contacts
Public ContactXiao Rong
The Second Xiangya Hospital of Central South University
Outcome results
None listed